The U.S. Food and Drug Administration (FDA) is offering a funding opportunity (NOFO RFA-FD-24-010) aimed at identifying drug-related and formulation-related factors that contribute to alcohol dose dumping (ADD) in modified-release (MR) oral drug products. The objective of this initiative is to develop tools that minimize the potential for ADD, thereby supporting regulatory assessments and enhancing the safety of generic medications. This research is crucial as it addresses the health risks associated with the rapid release of drugs when exposed to alcohol, which can lead to severe side effects. Funding of up to $250,000 is available for one year, with applications due by April 8, 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov for further information.